沙比利-缬沙坦治疗低射血分数心力衰竭的益处

Q4 Medicine Duzce Medical Journal Pub Date : 2022-12-30 DOI:10.47493/abantmedj.1182158

Lutfu Askin, Okan Tanriverdi

{"title":"沙比利-缬沙坦治疗低射血分数心力衰竭的益处","authors":"Lutfu Askin, Okan Tanriverdi","doi":"10.47493/abantmedj.1182158","DOIUrl":null,"url":null,"abstract":"Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Treatment with sacubitril/valsartan has been shown to significantly reduce mortality and hospitalization and rehospitalization rates for HF compared with enalapril. Sacubitril/valsartan may provide significant additional benefit in HF patients.","PeriodicalId":53622,"journal":{"name":"Duzce Medical Journal","volume":"67 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure\",\"authors\":\"Lutfu Askin, Okan Tanriverdi\",\"doi\":\"10.47493/abantmedj.1182158\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Treatment with sacubitril/valsartan has been shown to significantly reduce mortality and hospitalization and rehospitalization rates for HF compared with enalapril. Sacubitril/valsartan may provide significant additional benefit in HF patients.\",\"PeriodicalId\":53622,\"journal\":{\"name\":\"Duzce Medical Journal\",\"volume\":\"67 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Duzce Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47493/abantmedj.1182158\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Duzce Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47493/abantmedj.1182158","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

摘要

心力衰竭(HF)是由于外周血流量不足导致运动能力受损的原因。通过抑制尿钠素酶产生钠肽是心衰的治疗靶点。与依那普利相比，用苏比里尔/缬沙坦治疗可显著降低HF的死亡率、住院率和再住院率。Sacubitril/缬沙坦可能为HF患者提供显著的额外益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Treatment with sacubitril/valsartan has been shown to significantly reduce mortality and hospitalization and rehospitalization rates for HF compared with enalapril. Sacubitril/valsartan may provide significant additional benefit in HF patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊